Abstract
As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) to submit evidence for the clinical and cost effectiveness for previously treated chronic myeloid leukaemia (CML) and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). This paper focusses on the three phases of CML: the chronic phase (CP), the accelerated phase (AP) and the blast crisis phase (BP). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). This article presents the critical review of the company's submission by the ERG and the outcome of the NICE guidance. Clinical evidence for ponatinib was derived from a phase II, industry-sponsored, single-arm, open-label, multicentre, non-comparative study. Despite the limited evidence and potential for biases, this study demonstrated that ponatinib was likely to be an effective treatment (in terms of major cytogenetic response and major haematological response) with an acceptable safety profile for patients with CML. Given the absence of any head-to...Continue Reading
References
Jun 1, 1997·Journal of Clinical Epidemiology·H C BucherS D Walter
Sep 11, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van AgthovenC A Uyl-de Groot
Sep 13, 2003·Leukemia·E OlavarriaUNKNOWN Chronic Leukaemia Working Party of the European Group of Bone and Marrow Transplantation (EBMT)
Jul 15, 2005·Health Technology Assessment : HTA·A M GlennyUNKNOWN International Stroke Trial Collaborative Group
Apr 18, 2006·Current Treatment Options in Oncology·Merat Karbasian EsfahaniPeter H Wiernik
Mar 8, 2007·Cancer·Hagop KantarjianJorge Cortes
Apr 8, 2009·Journal of Clinical Epidemiology·Duncan ChambersNerys Woolacott
Apr 17, 2009·The Cochrane Database of Systematic Reviews·Jill FerrariTrevor D Prior
Aug 8, 2009·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Shelagh M SzaboJorge Cortes
Dec 16, 2010·Blood·Elias JabbourMarcos de Lima
Mar 23, 2011·Journal of Experimental Stroke & Translational Medicine·Scott R Evans
Apr 13, 2011·International Journal of Radiation Oncology, Biology, Physics·Ivan R Vogelius, Søren M Bentzen
Feb 3, 2012·BMC Medical Research Methodology·Patricia GuyotNicky J Welton
Mar 1, 2012·Blood·H Jean KhouryTim H Brümmendorf
May 9, 2012·Health Technology Assessment : HTA·E LovemanA Clegg
Nov 30, 2012·The New England Journal of Medicine·Jorge E CortesMoshe Talpaz
Feb 1, 2010·Therapeutic Advances in Hematology·Jerald P Radich
Jun 28, 2013·Blood·Michele BaccaraniRüdiger Hehlmann
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Dec 19, 2013·Blood·Hagop M KantarjianCarlo Gambacorti-Passerini
Jun 5, 2015·American Journal of Hematology·Carlo Gambacorti-PasseriniJorge E Cortes
Jan 29, 2016·BMJ Open·Andrew HillMark Bower
Apr 20, 2016·Cancer Epidemiology·Eve RomanRussell Patmore